Genexine, Inc.

KOSDAQ 095700.KQ

Genexine, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.71

Genexine, Inc. Price to Book Ratio (P/B) is 0.71 on January 14, 2025, a -50.57% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Genexine, Inc. 52-week high Price to Book Ratio (P/B) is 1.43 on January 15, 2024, which is 102.32% above the current Price to Book Ratio (P/B).
Genexine, Inc. 52-week low Price to Book Ratio (P/B) is 0.69 on December 09, 2024, which is -2.86% below the current Price to Book Ratio (P/B).
Genexine, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.04.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

KOSDAQ: 095700.KQ

Genexine, Inc.

CEO	Dr. Jungwon Woo Ph.D.
IPO Date	Sept. 15, 2009
Location	South Korea
Headquarters	Korea Bio Park Building B
Employees	86
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.

Key trends

Past 5 years